SAN FRANCISCO, June 2, 2016 /PRNewswire/ -- Nektar
Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled
to present at the upcoming Jefferies 2016 Global Healthcare Conference in New York City on
Wednesday, June 8, 2016 at 11:30 a.m. Eastern time.
The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of
the Nektar website: http://www.nektar.com. This Webcast will
be available for replay until July 8, 2016.
About Nektar
Nektar Therapeutics has a robust R&D pipeline and portfolio of approved partnered medicines in oncology,
pain, immunology and other therapeutic areas. In oncology, Nektar is developing NKTR-214, an immuno-stimulatory
CD122-biased agonist, that is in Phase 1/2 clinical development for patients with solid tumors. ONZEALD™ (etirinotecan pegol), a
long-acting topoisomerase I inhibitor, is being developed for patients with advanced breast cancer and brain metastases and
is partnered with Daiichi Sankyo in Europe. In the area of pain, Nektar has an exclusive worldwide license
agreement with AstraZeneca for MOVANTIK™ (naloxegol), the first FDA-approved once-daily oral peripherally-acting mu-opioid
receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic,
non-cancer pain. The product is also approved in the European Union as MOVENTIG® (naloxegol) and is indicated for adult
patients with OIC who have had an inadequate response to laxatives. NKTR-181, a wholly owned mu-opioid analgesic molecule for
chronic pain conditions, is in Phase 3 development. In hemophilia, Nektar has a collaboration agreement with Baxalta
for ADYNOVATE™ [Antihemophilic Factor (Recombinant)], a longer-acting PEGylated Factor VIII therapeutic approved in
the U.S. and Japan for patients over 12 with hemophilia A. In anti-infectives, the company has two
collaborations with Bayer Healthcare, Cipro Inhale in Phase 3 for non-cystic fibrosis bronchiectasis and Amikacin Inhale in
Phase 3 for patients with Gram-negative pneumonia.
Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships
with leading biopharmaceutical companies, including AstraZeneca's MOVANTIK™, Baxalta's ADYNOVATE™, UCB's Cimzia® for Crohn's
disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.
Nektar is headquartered in San Francisco, California, with additional operations
in Huntsville, Alabama and Hyderabad, India. Further information about the
company and its drug development programs and capabilities may be found online at http://www.nektar.com.
MOVANTIK™ is a trademark and MOVENTIG® is a registered trademark of the AstraZeneca group of companies.
ADYNOVATE™ is a trademark of Baxalta Inc.
ONZEALD™ is a trademark of Nektar Therapeutics.
Contact:
Investors
Jennifer Ruddock of Nektar Therapeutics
415-482-5585
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the-jefferies-2016-global-healthcare-conference-in-new-york-city-300279175.html
SOURCE Nektar Therapeutics